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Background: In the last decade, both endocrine and ultrasound data have been tested to verify their usefulness for
assessing ovarian reserve, but the ideal marker does not yet exist. The purpose of this study was to find, if any, a
statistical advanced model able to identify a simple, easy to understand and intuitive modality for defining ovarian
age by combining clinical, biochemical and 3D-ultrasonographic data.
Methods: This is a population-based observational study. From January 2012 to March 2014, we enrolled 652
healthy fertile women, 29 patients with clinical suspect of premature ovarian insufficiency (POI) and 29 patients with
Polycystic Ovary syndrome (PCOS) at the Unit of Obstetrics & Gynecology of Magna Graecia University of Catanzaro
(Italy). In all women we measured Anti Müllerian Hormone (AMH), Follicle Stimulating Hormone (FSH), Estradiol (E2),
3D Antral Follicle Count (AFC), ovarian volume, Vascular Index (VI) and Flow Index (FI) between days 1 and 4 of
menstrual cycle. We applied the Generalized Linear Models (GzLM) for producing an equation combining these
data to provide a ready to use information about women ovarian reserve, here called OvAge. To introduce this
new variable, expression of ovarian reserve, we assumed that in healthy fertile women ovarian age is identical to
chronological age.
Results: GzLM applied on the healthy fertile controls dataset produced the following equation OvAge = 48.05 -
3.14*AHM+ 0.07*FSH - 0.77*AFC - 0.11*FI + 0.25*VI + 0.1*AMH*AFC + 0.02*FSH*AFC. This model showed a high statistical
significance for each marker included in the equation. We applied the final equation on POI and PCOS datasets to test its
ability of discovering significant deviation from normality and we obtained a mean of predicted ovarian age significantly
different from the mean of chronological age in both groups.
Conclusions: OvAge is one of the first reliable attempt to create a new method able to identify a simple, easy
to understand and intuitive modality for defining ovarian reserve by combining clinical, biochemical and
3D-ultrasonographic data. Although design data prove a statistical high accuracy of the model, we are going to plan a
clinical validation of model reliability in predicting reproductive prognosis and distance to menopause.
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The normal process of reproductive ageing varies con-
siderably among women. While some women undergo
premature menopause, others have spontaneous preg-
nancy in their fourth decade of life [1]. This variability,
currently not predictable, is summarized in the concept
of ovarian reserve, a term coined more than 25 years
ago by Daniel Navot [2] and present in titles of at least
1300 papers indexed on PubMed.
Given this variability, the ability to predict the ovarian
reserve both in terms of reproductive prognosis and dis-
tance to menopause would be extremely important for
any modern physician and gynecologist, in guiding
patients’ reproductive attempts and in reducing the rates
of unnecessary surgeries for benign pathologies, for
which menopause may represent the best therapy.
Up to now, no test, neither single nor combined, pos-
sesses a satisfactory sensitivity and specificity for clinical
application [3]. The explanation to this incompetence
probably lies in the conundrum of any screening test for
ovarian reserve insufficiency: its prevalence changes with
age and the performance of any test changes with it [4].
This concept explains why no single threshold value is
usable to define an impairment of ovarian reserve, and
why every test should always be interpreted based on
the chronological patient’s age.
The ideal marker should be able to evaluate simultan-
eously the qualitative and quantitative aspects of ovarian
reserve, to integrate all the relevant information and
respond with an output of clear understanding, that we
could name “ovarian age”. Every woman could easily
compare this number with her chronological age and
the general practitioner would understand its meaning
without being an expert in reproductive medicine.
With this purpose, we introduce the new concept of
OvAge, a numeric variable, which accurately reflects the
ovarian reserve of women. Since the ovarian age is inher-
ently unknown, we assumed that OvAge coincides with
the chronological age, in healthy fertile women. A large
representative sample of the healthy fertile women popula-
tion has been used to design a statistical model able to es-
timate OvAge by a mathematical formula which accounts
for patient’s biochemical and ultrasonographic as predictor
variables. Biochemical variables include Follicle Stimu-
lating Hormone (FSH), Estradiol (E2), Anti Müllerian
Hormone (AMH), 3D-ultrasonographic variables are
Antral Follicle Count (AFC), ovarian volume, Flow index
(FI), Vascularization Index (VI) and Vascularization Flow
Index (VFI). We designed a Generalized Linear Model
(GzLM) and we finally used the model to evaluate the
clinical plausibility of OvAge estimations in women
with pathologic derangements of ovarian age, like pa-
tients with premature ovarian insufficiency (POI) and
polycystic ovary syndrome (PCOS). In particular, theincrease or decrease of OvAge from chronological age
were interpreted as a useful clinical index of physio-
pathological ovarian reserve.
Materials and methods
This is a population-based study including the data of
South Italy women enrolled after a delivery following a
spontaneous pregnancy, or during a routine visit for cer-
vical screening or contraception counselling at the Unit
of Obstetrics & Gynecology and analyzed in collabor-
ation with the Unit of Clinical Pathology and the School
of Informatics and Biomedical Engineering, at Magna
Graecia University of Catanzaro, Italy.
The study was approved by the local Ethics Committee
and written, informed consensus was obtained from
each woman to the anonymous use of clinical data for
statistical evaluation and research purposes.
From January 2012 to March 2014 we consecutively
recruited women, aged 18 to 55, who consent to partici-
pate in this prospective study, with history of spontan-
eous conception(s), intact ovaries and regular menses
with a mean interval of 21 to 35 days.
Exclusion criteria for the selection of the training sub-
jects for this model were: estrogen or progestin use or in
breastfeeding the two months before enrollment, preg-
nancy, history of female infertility, endometriosis, presence
of ovarian follicles measuring more than 10 mm at study
entry ultrasonography and other cystic masses of the ovary,
history of ovarian surgery, PCOS, gynecological malig-
nancy, previous radiation or chemotherapy, autoimmune
disease, known chronic, systemic, metabolic and endocrine
disease including hyperandrogenism, hyperprolactinemia,
diabetes mellitus and thyroid diseases, hypogonadotropic
hypogonadism or with history of use of drugs that can
cause menstrual irregularity.
During the same enrollment period, women with clin-
ical suspect of POI and women with PCOS were also
enrolled, to test the ability of OvAge to detect abnormal
deviation from chronological age.
POI was defined as the presence of secondary ame-
norrhea before the age of 40 years associated to FSH
value >30 U/L and clinical manifestations such as palpi-
tations, flushes, fatigue, anxiety, depression [5]. PCOS
was diagnosed according to the Rotterdam criteria [6],
when at least 2 of the following 3 features existed: oligo/
amenorrhea, clinical and/or biochemical hyperandrogen-
ism, and polycystic ovaries morphology (PCOM). We
chose to include only PCOS women with PCOM to test
our algorithm in this particular population of patients
because, notwithstanding the lack of absolute evidence
regarding dissimilarities involved in regulation of ovarian
ageing in these women, data currently available in litera-
ture suggest that the intrinsic ovarian abnormality asso-
ciated with altered follicular dynamics in the PCOS
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menopause and end of fertility [7].
At screening visit, all women were checked for inclu-
sion and exclusion criteria by anamnesis and clinical
examination. Anamnesis was collected by a standardized
questionnaire aimed to investigate also past problems in
conceiving and menstrual disorders.
Eligible women were asked to contact one of the in-
vestigators at the first day of menstrual cycle, at least
three to four months after delivery.
At study entry, basal AMH, FSH and E2, AFC, ovarian
volume, VI, FI and VFI were measured in all women
between day 1 and day 4 of menstrual cycle.
Hormonal assays
Blood samples obtained by venipuncture were centrifuged,
within 30 minutes from the collection, for 10 min at
3500 rpm, 4°C. Aliquots of each serum were frozen
at −80°C and stored for subsequent assays of AMH, FSH
and E2. To measure serum AMH levels, AMH-Gen II
ELISA assay kit (Beckman Coulter) was used. The lowest
detection limit of AMH is 0.08 ng/mL and the intra and
interassay coefficients of variation below 3.4% and 4.0%
respectively. The ECLIA method used to measure the
levels of serum FSH and E2 by COBAS e411 auto-analyser
(Roche Diagnostics). The lowest detection limit for FSH is
0.100 IU/L, with the intra- and interassay coefficients of
variation below 2.6% and 3.5% respectively. The lowest
detection limit for E2 is 18.4 pmol/L, with the intra-
and interassay coefficients of variation of 2% and 3%,
respectively.
Giving the poor reliability of the FSH value in presence
of Estradiol levels greater than 70 pg/mL, women with
basal E2 levels greater than this cut off were asked to
come back at the beginning of the subsequent menstrual
cycle, and their data were excluded from the analysis.
Ultrasonographic data collection and post-processing
The same day of hormonal assay, a single experienced
investigator (DL) performed all the ultrasound scans
using a Voluson-i (GE Healthcare Ultrasound) and a 5–
9-MHz transvaginal volume transducer, which has 3D
ultrasound scanning modes. Antral follicle number and
vascularization indices were measured using a 3D ul-
trasound dataset, with Sonography-based Automated
Volume Count and Virtual Organ Computer Aided Ana-
lysis Imaging Program (SonoAVC™ and VOCA™, GE
Healthcare Ultrasound, Zipf, Austria), as previously de-
scribed by other authors [8].
The acquired 3D ultrasound datasets were displayed in
the multiplanar view. The image were optimized to gen-
erate a three-dimensional volume of interest (VOI) and
to ensure that the whole ovary was included without
extra-ovarian information.SonoAVC was applied for automatically identifying
and quantifying hypoechoic areas within a 3D ultra-
sound dataset. Post-processing, involving the manual
identification of follicles not included in the previous au-
tomated analysis, was then used to ensure that all antral
follicles were counted. The total antral follicle count for
each subject was recorded to the nearest millimeter,
starting from 2.0 mm up to a maximum of 10.0 mm.
Patients with ovarian follicles greater than 10 mm were
asked to come back at the beginning of the subsequent
menstrual cycle.
The ultrasound machine was switched to the 3D mode
with power Doppler. The setting condition for this study
was as follows: frequency mid; dynamic set 2; balance
G >140; smooth 5/5; ensemble 12; line density 7; power
Doppler map 5, sweep angle 30°. The setting condition for
the sub-power Doppler mode was as follows: gain 6.0; bal-
ance 140; quality normal; wall motion filter low 1; velocity
range 0.9 kHz. A 3D dataset was then acquired using the
medium speed sweep mode. The built-in VOCAL (virtual
organ computer aided analysis) Imaging Program for the
3D power Doppler histogram analysis was used to deter-
mine the ovarian volume and indices of vascularization
and blood flow. Vascularization index (VI) measured the
number of blood vessels in the ovary (colour voxels) and
was expressed as a percentage (%) of the ovarian volume.
Flow index (FI) represented the average intensity of flow
inside the ovary and Vascularization flow index (VFI),
made by multiplying VI and FI, was a combination of
vascularization and flow. During the analysis and calcula-
tion, the manual mode of the VOCAL Contour Editor was
used to cover the whole 3D volume of the ovary with a
15° rotation step. Hence, 12 contour planes were ana-
lyzed for each ovary to cover 180°.
The intra-observer reliability was expressed as the
mean intra-class correlation coefficient (ICC) with 95%
confidence interval (CI). The mean ICC (95% CI) for 3D
scanning of ovarian volume, VI, FI and VFI were 0.9709
(0.8692, 0.9837), 0.9796 (0.9659, 0.9876), 0.8876 (0.7143,
0.9723) and 0.9934 (0.9761, 0.9987) respectively. The
mean ICC for data acquisition of ovarian volume, VI, FI
and VFI were 0.9945 (0.9745, 0.9923), 0.9845 (0.9432,
0.9954), 0.9878 (0.9621, 0.9954) and 0.9865 (0.9523,
0.9967) respectively.
Statistical analysis
A dataset of 710 records of subjects has been analyzed
using Konstanz Information Miner (KNIME) v.2.9.2 and
KNIME R Statistics Integration v.2.9.1 for integrating R
language v.3.0.3.
The whole analysis consists in six main steps: (i) defin-
ition and creation of three datasets, Healthy Controls,
POIs and PCOS; (ii) descriptive statistics and statistical
analysis of datasets and construction of growth curves
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alized Linear Models (GzLMs); (iv) choice of best model
by stepwise selection, according to the Aikake Informa-
tion Criterion (AIC) [10]; (v) reconstruction and refine-
ment of the best GzLM model; (vi) evaluation and
testing of the final model; (vii) application of the model
on POI and PCOS datasets.
For details of statistical methods, see the Additional
file 1.
Results
From January 2012 to March 2014, 840 women were
screened for the enrollment. According to exclusion and
inclusion criteria, 96 patients were not considered eli-
gible and other 34 refused to participate, hence a total of
710 women were enrolled and analyzed.
Table 1 summarizes the statistics of healthy controls
(HC, 652 subjects), POIs (29 subjects) and PCOS (29 sub-
jects) respectively, for age, parity, AMH, FSH, E2, AFC, FI,
VI, VFI and Volume. Spearman’s test coefficients showed
statistical dependences between Age and AMH (−0.8090),
FSH (0.6742), E2 (−0.2289), AFC (−0.7304), FI (−0.5649),
VI (−0.4066), VFI (−0.3428) and Volume (−0.5519). Holm’s
method corroborated this correlation, providing significant
adjusted p-values (p < 0.0001) for each dependent variable.
In Figure 1 the centile curves are depicted for each feature.
Table 2 presents a summary of the ten models accord-
ing to the predictors chosen for the equation and reports
AIC, the testing errors evaluated through the leave-one-
out (LOO) and cross-validation technique.
In the first model, GzLM#1, only E2, VFI and Volume
had shown p-values greater than 0.01. These three vari-
ables were then removed and a second model, GzLM#2,
was created. In GzLM#2, all the five variables showed a
p-value < 0.001, that together with the lowest AIC (and theTable 1 Descriptive statistics for healthy control subjects
(652 subjects), POI affected subjects (29 subjects) and







Age [years] 36.80 ± 8.62 37.90 ± 3.31 27.45 ± 4.30
Parity [number] 1.37 ± 0.97 0.44 ± 0.57 1.21 ± 0.67
AMH [ng/ml] 1.74 ± 1.75 0.01 ± 0.04 7.19 ± 2.13
FSH [mlU/ml] 12.47 ± 11.94 59.37 ± 23.52 6.45 ± 1.44
E2 [pg/ml] 40.76 ± 18.56 26.24 ± 17.02 49.90 ± 15.53
AFC 10.97 ± 6.71 3.24 ± 2.23 28.90 ± 6.51
FI 32.16 ± 9.46 22.38 ± 6.94 38.14 ± 6.35
VI 1.91 ± 2.68 1.46 ± 2.97 1.81 ± 0.98
VFI 1.11 ± 1.70 0.63 ± 0.85 1.26 ± 0.70
Volume 5.66 ± 2.25 3.72 ± 1.76 7.72 ± 1.98
Data are expressed as mean ± SD.highest leave-one-out and 10-fold cross-validation accur-
acy) leaded to accept this set of attributes as the best one.
The model GzLM#2* contains two more terms, AMH:
AFC (p-value < 0.001) and FSH:AFC (p-value < 0.001).
GzLM#2* showed a lower AIC value (3955.2) compared
to the previous models. ANOVA test was performed for
comparing model GzLM#2* to the null model: a p-value
< 0.001 for AMH, FSH, AFC, FI, AHM:AFC, FSH:AFC
and a p-value < 0.01 for VI, successfully confirmed the
prediction power of the variables.
The goodness of fitness of the model GzLM#2* was
first evaluated by a Chi-squared test obtaining a p-value
of 1, which was large enough to indicate no evidence of
a lack of fit.
In the upper part of the Figure 2a, diagnostic plots for
model GzLM#2* are depicted. In the plot on the left,
Pearson residuals were plotted against predicted values.
The red line almost coincides with the horizontal one
proving that the constant variance assumption on the
errors is verified and thus that the model shows a high
level of fit.
The Normal Q-Q plot on the right of the upper part
of Figure 2a shows that dots follow a linear trend even if
several cases at the ends influence the normality. For
this reason, the model, now called GzLM#2**, has been
updated without influence cases. Seven cases in total
have been removed from the final dataset and then ana-
lyzed by specialists in order to search for possible abnor-
malities. Such further investigation showed that those
patients were not affected by any pathology and the only
reason for excluding them is related to their high Cook’s
distance, that is the measure of influence on the regres-
sion coefficients.
The bottom part of the Figure 2b depicts diagnostic
plots for the new GzLM#2** model. The Normal Q-Q
plot still shows several cases diverge from linearity but
their distances are acceptable, compared to the Normal
Q-Q plot of GzLM#2*. The red line in the plot of resid-
uals against the fitted values of GzLM#2** (on the left),
presents a slight improvement in the linear trend com-
pared to the plot of model GzLM#2*.
The LOO and ten-fold cross-validation accuracy for
GzLM#2** are respectively 79.865% and 79.832%, with
an improvement of about 3% of accuracy compared to
the previous models.
For these reasons, we can certainly assess that in our
dataset of 645 healthy controls, the best equation for
predicting the ovarian age is: OvAge = 48.05-3.14*AHM+
0.07*FSH-0.77*AFC-0.11*FI + 0.25*VI + 0.1*AMH*AFC +
0.02*FSH*AFC.
GzLM#2** has been applied on POI and PCOS data-
sets to test its power of discovering significant deviation
from normality. The ovarian age of each POI subject
resulted to be, as expected, significantly higher than the
Figure 1 Plots of growth curve centile (3th, 10th, 25th, 50th, 75th, 90th, 97th) for each feature where Age is the covariate. The LMS
method and penalized likelihood is used for fitting distributions.
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Table 2 Comparison of Generalized Linear Models in term
of AIC as the predictors change
Model Predictor AIC
GzLM#1 AMH + FSH + E2 + AFC + FI + VI + VFI + Volume 3987.3
GzLM#2 AMH + FSH + AFC + FI + VI 3981.9
GzLM#2* AMH + FSH + AFC + FI + VI + AMH*AFC + FSH*AFC 3955.2
GzLM#3 AMH 4175.5
GzLM#4 AMH + FSH 4052.1
GzLM#5 AMH + FSH + E2 4053.8
GzLM#6 AMH + FSH + AFC 4003.4
GzLM#7 FI + VI + VFI + Volume 4449.9
GzLM#8 AFC 4215.6
GzLM#9 AFC + Volume 4190
GzLM#10 Volume 4651.7
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50.63 ± 3.80 years, against a mean of chronological age
of 37.90 ± 3.31 years.
Regarding PCOS subjects, the mean OvAge (24.98 ±
0.91 years) of 24 PCOS subjects resulted to be signifi-
cantly lower than the chronological age (29 ± 2.75 years).
Discussion
In this prospective study, we collected data of clinical,
biochemical and 3D-ultrasonographic parameters in a
population of healthy fertile women with the aim of
developing a new methodology to quantify ovarian age
(OvAge). To introduce this new variable, expression of
ovarian reserve, we assumed that in healthy women with
proven fertility ovarian age corresponds to chronological
age.
In women enrolled as healthy fertile controls, our new
model showed a high level of fit between chronological
age and predicted OvAge. In POIs and PCOS patients,
conversely, a significant difference between these two
parameters was shown, indicating that the formula pro-
duced is able to recognize pathological deviation from
normal ovarian function.
Moreover, in all 18 women with a predicted ovarian
age between 49 and 51 years at enrollment, regardless of
their chronological age, menopause occurred within 1–2
years during the study period (data not shown).
Although preliminary, these results are very promising
and drive us to further investigations and to a follow-up
clinical validation of our model. The prospective evalu-
ation of distance to menopause in our population, for
example, is ongoing, and our statisticians are working to
reach quickly the highest possible predictive ability, by
means of accelerated failure time modeling. This ap-
proach was recently used by Tehrani et al. [11], but their
analysis was conducted by measuring AMH, collected
on any days of the menstrual cycles, and they did notuse other markers of ovarian ageing [11]. The evaluation
of our 18 cases in which OvAge was more reliable than
chronological age in determining the time to meno-
pause, however, is already a first clinical confirmation of
its reliability.
With OvAge, we aim to answer the need of any mod-
ern gynecologist to find the ideal marker of ovarian
function. It should be universally accepted, reproducible,
easy to interpret and applicable to the general popula-
tion, and has to be able to give reliable information on
number and quality of follicles, residual fertility, time to
menopause and reproductive prognosis, both natural
and post-Assisted Reproductive Techniques (ART).
Basal serum FSH, extensively studied over the past few
decades, only provides a crude surrogate marker of bio-
logical ovarian age when paired with the chronological
age but it is probably the most indirect marker of
ovarian reserve to date [12]. Moreover, FSH variability
between follicular phases has been reported to be above
50% of the measured value, thus inevitably reducing the
global predictive performance of this marker [13].
Recent studies have suggested that serum AMH levels
represent ovarian quantitative reserve in IVF patients and
may provide an index of age at menopause [11,14,15].
Thanks to its ability of providing valuable information
regardless of what day in the cycle the sample is drawn
and in women who do not menstruate, AMH has gained
popularity among infertility specialists. In a recent retro-
spective study on women undergoing their first IVF/ICSI
cycle, however, concordance between AMH and FSH was
noted in 57% of women while 43% of women had discord-
ant values. According to these results, authors concluded
that both AMH and FSH tests are probably useful to pre-
dict ovarian response but since many women have dis-
cordant values, it is difficult to counsel patients regarding
their true ovarian reserve using one single marker [16].
In a recent meta-analysis, authors showed that even if
AMH, independently of age, has some association with
predicting live birth after assisted conception, its predict-
ive accuracy is poor, concluding that no patient should
be precluded from attempting ART solely on the basis of
an AMH value [17]. Moreover, only very limited data on
AMH and natural fertility at different stages of repro-
ductive life are available today, since AMH levels have
been extensively studied in infertile women but less in
fertile ones.
With the recent acquisition of one of the two commer-
cially available assays in commerce by Beckman-Coulter,
the two existing kit were replaced by a new enzyme-
linked immunosorbent assay. Recent safety notices, indi-
cating the risk of falsely low and falsely elevated values
due to technical mistakes, have fueled concerns about
the robustness of the new assay [18]. This issue, once
again, limits the actual possibility of considering AMH
Figure 2 Diagnostic plots for (a) model GzLM#2* and (b) model GzLM#2**. On the left Pearson residuals plotted against predicted values
and on the right the Normal Q-Q plot. The red line in the plot of residuals of GzLM#2** presents a slight improvement in the linear trend
compared to the plot of model GzLM#2*.
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reserve assessment.
Studies on ultrasonographic parameters and ovarian
reserve prediction reported similar conclusions. While
AFC provides a direct estimation of recruitable follicles
and gradually declines with chronological age, less data
are today available on ovarian flow indexes [19].
According to the results of his meta-analysis, Gibreel
in 2009 concluded that although Doppler studies of
ovarian stromal blood flow are promising, more studies
are warranted, also to determine the optimum parame-
ters and the best cut-off values for these indices [20]. It
is known, however, that three-dimensional Doppler tech-
nique yields better axial resolution, fewer bloomingartifacts, and improved sensitivity to slow flows and
small vessels compared with standard bi-dimensional
power Doppler [21]. This advantage makes 3D angiog-
raphy attractive since one speculative cause of age-related
increase in oocyte chromosomal meiotic errors is a re-
duced oxygen levels in the follicular fluid caused by a com-
promised microcirculation around the leading follicle [22].
All these observations confirm the need of assessing
ovarian age through dynamic multimodal tools able to
improve the limited accuracy of the single parameter
evaluated individually.
To the best of our knowledge, this is the first attempt to
create a multimodal methodology able to answer with an
easy-to-interpret response, the exact ovarian age or OvAge.
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uations and gives as a result explicitly the ovarian age, a
ready-to-use information, which will be useful for both
women and physicians. In future, if it will be validated by
our ongoing prospective evaluation, OvAge could provide
reliable information to gynecologists for counseling pa-
tients in their reproductive attempts and for reducing the
rates of unnecessary surgery in the management of benign
pathologies, such as dysfunctional abnormal uterine bleed-
ing, adenomyosis or fibromatous uterus, which may best
be treated with medical therapy, if natural menopause will
be predicted to occur within few years.
OvAge could help researchers in quantifying the effect
of surgeries, medications and ovarian pathologies them-
selves on women’s ovarian in term of years of ageing,
with the advantage of an intuitive, easily communicable
and universal information available to both physicians
and patients.
Conclusions
In conclusion, to the best of our knowledge, this is the first
attempt to build a mathematical formula in which, once
single patient’s biochemical and ultrasonographic values
are introduced as input, the generated output is an easy-
to-interpret number, which reliably expresses the ovarian
reserve of that woman. This formula and its output, both
called OvAge, put together different markers with differ-
ent meanings to increase the reliability of the new ovarian
reserve parameter.
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